Skip to main content
Equibles

UBS Group AG

Position in CGEM — Cullinan Therapeutics, Inc.

CIK 1610520 ZURICH, V8
Back to CGEM Full portfolio

Position in CGEM

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$4,527,495
+$1,651,605 QoQ
Shares Held
248,627
+22.8% QoQ
Ownership
0.386%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#40
of 183 holders
Holding Since
Mar 2021
22 quarters on record
Voting authority Sole 55% Shared 0% None 45%

Common Shares in CGEM Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,801 across 560 Biotechnology names. CGEM ranks #155 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in CGEM

Export CSV
22 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,527,495 248,627
2026-03-31 $2,875,890 202,385
2025-12-31 $2,812,467 271,736
2025-09-30 $1,115,936 188,185
2025-06-30 $2,344,156 311,309
2025-03-31 $2,110,659 278,819
2024-12-31 $2,870,983 235,713
2024-09-30 $3,106,156 185,553
2024-06-30 $2,790,050 159,980
2024-03-31 $2,841,248 166,740
2023-12-31 $1,434,537 140,779
2023-09-30 $936,339 103,463
2023-06-30 $979,880 91,067
2023-03-31 $1,033,761 101,052
2022-12-31 $1,035,513 98,153
2022-09-30 $1,167,478 91,067
2022-06-30 $1,176,567 91,776
2022-03-31 $1,307,796 124,909
2021-12-31 $335,478 21,742
2021-09-30 $90,121 3,993
2021-06-30 $50,624 1,966
2021-03-31 $128,884 3,093